RxDoctor Payments Data

Randolph Shey, MD

Neurology · Long Beach, CANPI 1417997636

Payments from drug & device makers

$27,953in general payments, 2019–2025

Across 1,410 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$2K
  • UCB, Inc.$2K
  • AstraZeneca$2K
  • Biogen$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$650%
  • Food & beverage$27,22697%
  • Education$6622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis162$2,583
AbbVie(2 entities)137$2,253
Neurocrine Biosciences, Inc.103$2,118
UCB, Inc.72$1,724
AstraZeneca(2 entities)84$1,673
Biogen74$1,459
Teva Pharmaceuticals USA, Inc.69$1,417
MDD US Operations, LLC73$1,255
Pfizer43$989
Amgen(2 entities)54$983
EMD Serono, Inc.45$931
Lilly USA, LLC43$875
Acadia Pharmaceuticals Inc38$811
CSL Behring25$749
Lundbeck LLC36$729
Sanofi22$512
SK Life Science, Inc.26$497
Bristol Myers Squibb21$483
Kyowa Kirin, Inc.20$395
Genentech USA, Inc.14$390
Sunovion Pharmaceuticals Inc.22$369
Vanda Pharmaceuticals Inc.11$290
Argenx US, Inc.12$282
Alnylam Pharmaceuticals Inc.11$280
Otsuka America Pharmaceutical, Inc.12$274
Takeda Pharmaceuticals U.S.A., Inc.11$249
Biohaven Pharmaceuticals, Inc.15$210
Johnson & Johnson(2 entities)14$209
Biohaven Pharmaceutical Holding Company Ltd.14$203
Sumitomo Pharma America, Inc.10$198
Eisai Inc.7$165
Amylyx Pharmaceuticals, Inc.5$144
Supernus Pharmaceuticals, Inc.9$143
Upsher-smith Laboratories LLC7$135
Averitas Pharma Inc.4$135
Tanabe Pharma America, Inc.6$134
Acorda Therapeutics, Inc6$132
Scilex Pharmaceuticals Inc.6$126
Mallinckrodt Enterprises LLC4$93
Aucta Pharmaceuticals, Inc.6$93
Merz Pharmaceuticals, LLC3$92
Grifols USA, LLC4$88
Neurelis, Inc.4$84
Abbott5$83
Ipsen Biopharmaceuticals, Inc3$78
Adamas Pharmaceuticals, Inc.4$76
GE HealthCare4$75
Harmony Biosciences LLC2$69
Livanova USA, Inc.3$66
Greenwich Biosciences, Inc.2$62
Amneal Pharmaceuticals LLC2$58
Catalyst Pharmaceuticals, Inc.2$49
Forte Bio-pharma LLC2$43
Idorsia Pharmaceuticals US Inc2$36
ANI Pharmaceuticals, Inc.1$34
Corium, LLC1$29
Jazz Pharmaceuticals Inc.1$29
Vertical Pharmaceuticals, LLC1$23
Neuropace, Inc.1$23
Aquestive Therapeutics, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,953 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$192,163
Medicare patients
437
Services billed
1,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FingolimodFingolimod Hcl20$93,392
CopaxoneGlatiramer Acetate13$74,599
Memantine Hcl ErMemantine Hcl160$19,877
Dalfampridine ErDalfampridine25$19,683
Ajovy AutoinjectorFremanezumab-Vfrm18$18,576
Memantine Hcl438$13,413
OngentysOpicapone17$12,021
Gabapentin634$8,537
Carbidopa-LevodopaCarbidopa/Levodopa184$6,829
Levetiracetam142$6,165
Rasagiline Mesylate32$5,732
Lacosamide42$4,921
Donepezil Hcl323$4,156
DilantinPhenytoin Sodium Extended14$4,089
Entacapone14$3,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$1,417$74,59913 claims
Neurocrine Biosciences, Inc.Ongentys$2,118$12,02117 claims
PfizerDilantin$989$4,08914 claims
Upsher-smith Laboratories LLCTopiramate$135$47143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →